As 2026 begins, the global hepatology community is closely monitoring a wave of breakthrough data from Phase II and III trials that aim to permanently correct the ATP7B genetic mutation. Regulatory authorities in the European Union and the United States have recently signaled a willingness to accept biomarker-driven endpoints, such as long-term reduction in non-ceruloplasmin bound copper, to...

Physician biosimilar education — addressing prescriber concerns about biosimilar safety, switching consequences, and interchangeability — remains the most important demand-side factor in biosimilar market penetration, with the Biosimilars Market reflecting prescriber behavior as the critical adoption determinant beyond regulatory and pricing factors. Biosimilar prescriber...

C-Reactive Protein Testing Market Size, Share, Industry Analysis & Forecast 2033 Introduction C-Reactive Protein Testing Market is experiencing steady growth as healthcare providers increasingly rely on diagnostic biomarkers to detect inflammation, infections, and cardiovascular conditions. C-reactive protein (CRP) is a substance produced by the liver in response to inflammation, and...

Gemcitabine is a widely used chemotherapy medication that plays a crucial role in the treatment of various cancers, including pancreatic, breast, ovarian, bladder, and non-small cell lung cancer. The increasing global burden of cancer, coupled with advancements in oncology treatment protocols, is driving demand for effective chemotherapeutic agents. Growing healthcare investments and improved...

The Biosimilars Market continues to evolve rapidly with the growing acceptance of biosimilar medicines among physicians, healthcare providers, and patients. These therapies offer similar efficacy and safety as originator biologics while significantly lowering healthcare expenses. Increasing investments in biotechnology, rising prevalence of autoimmune disorders and cancer, supportive regulatory...

The "Cost of Innovation" is being slashed this year thanks to common-sense regulatory reform. In 2026, the US Biosimilars Market is benefiting from the FDA’s new "Science-First" approach to drug approvals. Historically, biosimilar developers were required to conduct massive, multi-year clinical trials to prove their product was "Equivalent" to the brand-name drug. However, as of March...